false00011093540001109354us-gaap:CommonStockMember2026-11-122026-11-1200011093542026-11-122026-11-120001109354brkr:SixPointThreeSevenFivePercentageMandatoryConvertiblePreferredStockSeriesAMember2026-11-122026-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2026
BRUKER CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
000-30833 |
04-3110160 |
(State or other jurisdiction of |
(Commission |
(I.R.S. Employer |
incorporation) |
File number) |
Identification No.) |
40 Manning Road
Billerica, MA 01821
(Address of principal executive offices) (Zip Code)
(978) 663-3660
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
Common Stock, $0.01 par value per share |
|
BRKR |
|
The Nasdaq Global Select Market |
6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share |
|
BRKRP |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 5 – Corporate Governance and Management
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Election of New Director
On November 13, 2026, the Board of Directors (the “Board”) of Bruker Corporation (the “Company”) approved an increase in the number of directors to expand the size of the Board by one director to a total of twelve directors, with such additional director assigned to Class II, and appointed Eicke Latz MD PhD to fill the newly created vacancy on the Board, effective as of January 1, 2027. Dr. Latz will initially serve as a director until the 2029 Annual Meeting of Stockholders.
Dr. Latz’s compensation for his services as a director will be consistent with that of the other non-employee directors of the Company, as described in the Company’s definitive proxy statement with respect to the 2026 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 10, 2026. There are no other arrangements or understandings between Dr. Latz and any other person pursuant to which he was elected as a director, and Dr. Latz is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.
The Company will file an amended Form 8-K to disclose Dr. Latz’s committee assignments once determined.
A copy of the press release announcing Dr. Latz’s appointment is attached to this report as Exhibit 99.1.
Section 8 - Other Events
Item 8.01. Other Events.
The Board declared a quarterly cash dividend on the Company’s common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on November 12, 2026, and is payable January 7, 2027, to shareholders of record at the close of business on December 21, 2026.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
|
|
|
|
(d) |
Exhibits. |
|
|
|
|
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release dated November 16, 2026. |
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
BRUKER CORPORATION (Registrant) |
|
|
Date: November 16, 2026 |
By: |
/s/ THOMAS M. BURES |
|
|
Thomas M. Bures |
|
|
Chief Accounting Officer |

Professor Eicke Latz has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics. His entrepreneurial efforts have focused on translating cutting-edge discoveries in innate immunity and inflammation into novel therapeutic approaches, with programs advancing into clinical development and leading to successful exits and initial public offerings. Through his biopharma ventures, Dr. Latz is bridging fundamental disease biology insights to therapeutic innovation, unmet medical needs and value creation.
Exhibit 99.1
Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors
BILLERICA, Massachusetts – November 16, 2026 – Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized medical institute director, physician-scientist, successful biopharma entrepreneur, and innovation leader. His work is transforming the understanding of innate immunity and inflammation, while also advancing numerous therapeutic programs from discovery to clinical development.
Frank H. Laukien, chairman, president and CEO of Bruker Corporation, stated: “Eicke brings a rare combination of world-class disease biology leadership, remarkable biopharma entrepreneurial success, and medical institute strategic leadership to our board. As Bruker expands its leadership in post-genomic life-science tools for disease biology research, molecular diagnostics, and biopharma drug discovery and development, Eicke’s scientific-medical vision, biopharma insights, strategic and leadership experience will be very valuable to Bruker.”

Dr. Latz is also a highly respected scientific and organizational leader. He is the Scientific Director of the German Rheumatology Research Center (DRFZ) and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin, having previously founded and directed the Institute of Innate Immunity at the University of Bonn. His leadership extends across academia medical centers, biopharma industry, and governmental advisory work on venture formation and scaling, to senior advisory roles with major pharmaceutical companies.
“It’s a great honor to join the Board of Directors at Bruker Corporation, a company at the forefront of AI-accelerated, deep functional proteomics, multiomics and spatial biology research,” said Dr. Latz. “I see Bruker as uniquely positioned to enable significant advancements
in disease biology research, novel biomarker discovery, and next-generation proteomic molecular diagnostics, and I am very excited to contribute.”
About Bruker Corporation – Leader of the Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Forward-Looking Statements
Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com